Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy - A 10-year population-based cohort study

Prostate

Volumn 75, Issue 9, 2015, Pages 947-956

  Aly, Markus ^a,b   Dyrdak, Robert ^b,c   Nordström, Tobias ^a,b   Jalal, Shah ^c,d   Weibull, Caroline E ^b   Giske, Christian G ^b,c   Grönberg, Henrik ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Unilabs   (France)

Author keywords

antimicrobial resistance; biopsy; blood stream infection; complications; prostate

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CIPROFLOXACIN; GENTAMICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLI; BLOOD CULTURE; BLOODSTREAM INFECTION; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; ENTEROBACTERIACEAE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; STAPHYLOCOCCUS AUREUS; SWEDEN; ADVERSE EFFECTS; BACTEREMIA; BIOPSY; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROSTATE; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BIOPSY; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PROSTATE; RETROSPECTIVE STUDIES; SWEDEN;

EID: 84929989847     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22979     Document Type: Article

References (25)

1. Carignan A, Roussy J-F, Lapointe V, Valiquette L, Sabbagh R, Pépin J,. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: Time to reassess antimicrobial prophylaxis? Eur Urol 2012; 62 (3): 453-459.
2. Rudzinski JK, Kawakami J,. Incidence of, infectious complications, following transrectal ultrasound-guided prostate biopsy in Calgary Alberta, Canada: A retrospective population-based analysis. Can Urol Assoc 2014; 8 (5-6): E301-E305.
3. Aron M, Rajeev TP, Gupta NP,. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85 (6): 682-685.
4. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y,. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64 (6): 876-892.
5. Lundström K-J, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, Bill-Axelson A,. Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy. J Urol 2014; 192 (4): 116-122.
6. Cuevas O, Oteo J, Lázaro E, Aracil B, de Abajo F, García-Cobos S, Ortega A, Campos J,. Spanish EARS-Net Study Group. Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid. J Antimicrob Chemother 2011; 66 (3): 664-669.
7. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, Ferech M,. European Antimicrobial Resistance Surveillance System Group, European Surveillance of Antimicrobial Consumption Project Group. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14 (11): 1722-1730.
8. Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, Vankerckhoven V, Aerts M, Hens N, Molenberghs G, Goossens H, ESAC Project Group,. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011; 66 (suppl 6): vi3-v12.
9. Hellman J, Aspevall O, Bengtsson B, Greko C,. editors. SWEDRES SVARM [Internet]. Public Health Agency of Sweden and National Veterinary Institute, 2013; Available from: www.folkhalsomyndigheten.se/publicerat-material/.
10. Nordström T, Aly M, Clements MS, Weibull CE, Adolfsson J, Grönberg H,. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: Results from a population-based study, 2003-2011. Eur Urol 2013; 63 (3): 419-425.
11. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A,. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24 (11): 659-67.
12. Vårdprogram 2007 Prostatacancer [Internet]. 2007 [cited 2014 Sep 30]. Available from: http://www.karolinska.se/upload/Onkologiskt%20centrum/RegionalVardprogram/Prostata2007.pdf
13. Vårdprogram för prostatacancer 2004. ISBN 91-85738-61-1
14. Vårdprogram för Prostatacancer 2008. ISBN 91 85738 79 4
15. Lindstedt S, Lindström U, Ljunggren E, Wullt B, Grabe M,. Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur Urol 2006; 50 (4): 832-837.
16. Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R,. Infection after transrectal ultrasonography-guided prostate biopsy: Increased relative risks after recent international travel or antibiotic use. BJU Int 2012; 109 (12): 1781-1785.
17. Lausch KR, Fuursted K, Larsen CS, Storgaard M,. Colonisation with multi-resistant Enterobacteriaceae in hospitalised Danish patients with a history of recent travel: A cross-sectional study. Travel Med Infect Dis 2013; 11 (5): 320-323.
18. Peirano G, Laupland KB, Gregson DB, Pitout JDD,. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med 2011; 18 (5): 299-303.
19. Andersson P, Remvig H,. Så reser svenskarna [Internet]. 2013 [cited 2014 Sep 29]. Available from: http://www.vagabond.se/artiklar/nyheter/20130528/sa-reser-svenskarna.
20. Tängdén T, Cars O, Melhus A, Löwdin E,. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: A prospective study with Swedish volunteers. Antimicrob Agents Chemother. Am Soc Microbiol 2010; 54 (9): 3564-3568.
21. Titelman E, Hasan CM, Iversen A, Nauclér P, Kais M, Kalin M, Giske CG,. Faecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors. Clin Microbiol Infect. 2014; 20 (8): O508-O515.
22. Batura D, Rao GG, Nielsen PB,. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 2010; 106 (7): 1017-1020.
23. Park DS, Hwang JH, Choi DK, Gong IH, Hong YK, Park S,., Oh JJ,. Control of infective complications of transrectal prostate biopsy. Surg Infect (Larchmt) 2014; 15 (4): 431-436.
24. Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, O'Reilly M, Murphy D,. Sepsis and "superbugs": Should we favour the transperineal over the transrectal approach for prostate biopsy. BJU Int. 2014; 114 (3): 384-388.
25. Carlsson SV, Holmberg E, Moss SM, Roobol MJ, Schröder FH, Tammela TLJ, Aus G, Auvinen AP, Hugosson J,. No excess mortality after prostate biopsy: Results from the European Randomized Study of Screening for Prostate Cancer. BJU Int 2011; 107 (12): 1912-1917.